Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

HEAL-COVID Team +44 (0) 151 794 0222
trial.team@heal-covid.net


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)

HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)

Not Recruiting

Open to: ALL

Age: 18.0 - N/A

Medical Conditions

COVID-19


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


HEAL-COVID is jointly Sponsored by Cambridge University Hospitals NHS Foundation Trust and The University of Cambridge.

The acute effects of COVID-19 are now well described. Evidence is emerging of serious longer-term complications occurring in the convalescent phase of the illness in a significant proportion of patientsÍľ particularly cardiovascular and pulmonary complications.

The ill-defined syndrome, "Long COVID" is likely to include a constellation of different conditions traversing post-ICU syndromes, significant cardiopulmonary complications, post-viral syndromes and exacerbations of underlying conditions. Patients have reported a range of longer-term symptoms associated with Long COVID that have significant impacts on their quality of life.

To date, there has been little work evaluating treatments in the convalescent phase of COVID-19. HEAL-COVID aims to evaluate the impact of treatments on longer-term morbidity, mortality, re-hospitalisation, symptom burden and quality of life associated with COVID-19.

The first two treatment arms are Apixaban and Atorvastatin, with further treatment arms to be added at the direction of the UK COVID-19 Therapeutic Advisory Panel (UKCTAP).

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

May 2021 Jan 2024

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Apixaban 2.5mg orally twice daily for 14 days.

Intervention Arm Group : Apixaban;

Intervention Type : DRUG
Intervention Description : Atorvastatin 40mg orally once daily for 12 months.

Intervention Arm Group : Atorvastatin;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Addenbrookes Hospital
    Cambridge


The study is sponsored by Cambridge University Hospitals NHS Foundation Trust and is in collaboration with University of Liverpool; Cambridge University Hospitals NHS Foundation Trust (joint Sponsor); The University of Cambridge (joint Sponsor).




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT04801940
Last updated 19 July 2021

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.